Premium
Modeling the pharmacodynamics of nandrolone doping drug and implications for anti‐doping testing
Author(s) -
Sahin Özge,
Senturk Feyyaz,
Barlas Yaman,
Yasarcan Hakan
Publication year - 2020
Publication title -
system dynamics review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.491
H-Index - 57
eISSN - 1099-1727
pISSN - 0883-7066
DOI - 10.1002/sdr.1672
Subject(s) - finasteride , nandrolone , metabolite , pharmacodynamics , pharmacology , drug , steroid , pharmacokinetics , anabolic steroid , anabolism , chemistry , medicine , biochemistry , prostate , hormone , cancer
We model the pathways of nandrolone in the body, an anabolic steroid widely used as a performance enhancing drug (PED). The model generates the dynamics of nandrolone and its metabolites. PED tests check for the presence of a primary metabolite of nandrolone, 19‐NA in urine. To cheat in these tests, PED users typically use inhibitors that reduce the urinary concentration of 19‐NA. One such inhibitor is finasteride. Finasteride’s main effect in the body is the inhibition of reductase enzymes that turn nandrolone into its metabolite 19‐NA. To capture this effect, we include structures for finasteride and reductase enzymes in the model. The model is tested by fundamental structure validity tests. We also show that the model behavior is consistent with experimental data in the literature. We finally investigate the potential ways by which the drug users may cheat in PED tests and make suggestions for improved testing as counter‐measures. © 2021 System Dynamics Society